Microcap Ledger

Tickers · $IVVD

Invivyd, Inc. $IVVD

By Microcap Ledger desk · CIK 0001832038

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Global Market
Sector
Biological Products, (No Diagnostic Substances)
Headquarters
New Haven, CT
Fiscal year end
December 31
Shares outstanding
294,758,746 [10-Q 2026-08-13]
as of 2026-07-30

Sources: [10-K 2026-03-05]

What the company doesAI summary of filing

Invivyd, Inc. is a biopharmaceutical company developing monoclonal antibody therapies for prevention and treatment of serious viral infectious diseases, beginning with COVID-19. The company's first product, PEMGARDA (pemivibart), received emergency use authorization from the FDA in March 2024 for pre-exposure prophylaxis of COVID-19 in moderately to severely immunocompromised adults and adolescents. The company is advancing VYD2311, a next-generation mAb candidate for COVID-19, through clinical trials and has initiated Phase 3 development programs. Invivyd is also exploring mAb candidates for other infectious diseases including RSV and measles, and generates revenue from PEMGARDA commercialization while remaining dependent on regulatory authorization and clinical development success for future products. [10-K 2026-03-05]

Segments: PEMGARDA (pemivibart) - COVID-19 pre-exposure prophylaxis, VYD2311 - next-generation COVID-19 mAb candidate, VBY329 - RSV prevention candidate, Measles mAb candidates

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026$28.03M−$85.79M −$84.72M$160.08M[10-Q 2026-08-13]
FY ended Dec 2025$53.43M−$52.49M −$58.13M$226.69M[10-K 2026-03-05]
FY ended Dec 2024$25.38M−$169.93M −$170.49M$69.35M[10-K 2026-03-05]
Quarterly cash burn
−$42.36M
Cash runway Estimate
~11.3 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-01119,616,035[10-Q 2024-11-14]
2025-03-11119,961,445[10-K 2025-03-20]
2025-05-01119,961,445[10-Q 2025-05-15]
2025-08-01120,142,811[10-Q 2025-08-14]
2025-10-30233,122,834[10-Q 2025-11-06]
2026-02-26282,594,729[10-K 2026-03-05]
2026-04-30294,607,452[10-Q 2026-05-14]
2026-07-30294,758,746[10-Q 2026-08-13]
Shelf registration
S-3 filed 2025-10-02; declared effective 2025-12-23 [S-3 2025-10-02]

Listing status

Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-24. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

DateEventDetailsDeadlineFiling
2026-07-248-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2026-07-24]
2025-04-258-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2025-04-25]
2024-12-278-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2024-12-27]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-08-18Lee Timothy Edwardsell18,425$0.84[4 2026-08-18]
2026-08-18Green Juliesell18,425$0.84[4 2026-08-18]
2026-08-18Duke William E.sell18,425$0.84[4 2026-08-18]
2026-08-18Andersen Jillsell30,706$0.84[4 2026-08-18]
2026-08-18Allen Robert D. Iiisell17,043$0.84[4 2026-08-18]
2026-08-17Lee Timothy Edwardsell22,355$0.72[4 2026-08-18]
2026-08-17Green Juliesell22,355$0.72[4 2026-08-18]
2026-08-17Duke William E.sell22,355$0.72[4 2026-08-18]
2026-08-17Andersen Jillsell37,256$0.72[4 2026-08-18]
2026-08-17Allen Robert D. Iiisell20,679$0.72[4 2026-08-18]
2026-08-15Lee Timothy Edwardexercise102,000—[4 2026-08-18]
2026-08-15Green Julieexercise102,000—[4 2026-08-18]

Catalysts and calendar

Recent filings and releases
DateTypeTitle
2026-09-298-KOther events
2026-09-018-KDirector or officer change; Other events
2026-08-1413G/ABeneficial ownership report (5%+ holder)
2026-08-1413G/ABeneficial ownership report (5%+ holder)
2026-08-1310-QQuarterly report
2026-08-138-KResults of operations
2026-07-2813GBeneficial ownership report (5%+ holder)
2026-07-248-KListing notice or transfer
2026-07-068-KOther events
2026-05-198-KShareholder vote results
2026-05-1513G/ABeneficial ownership report (5%+ holder)
2026-05-1513G/ABeneficial ownership report (5%+ holder)

Facts as of . Small caps move fast; check the latest filings.